Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous cytokine-induced killer cells (Chinese PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous cytokine-induced killer (CIK) cells are an adoptive cellular immunotherapy being investigated by the Chinese PLA General Hospital for the treatment of chronic moderate to severe plaque psoriasis. The therapy involves the ex vivo expansion of a patient's own peripheral blood mononuclear cells (PBMCs) using a combination of interferon-gamma (IFN-γ), anti-CD3 monoclonal antibodies, and interleukin-2 (IL-2). This process generates a heterogeneous population of immune cells, predominantly CD3+CD56+ T cells, which possess both T-cell-like and natural killer (NK) cell-like properties. The therapeutic rationale is based on evidence that CD3+CD56+ cells are significantly decreased in patients with psoriasis; restoring these cell levels via intravenous infusion is intended to modulate the immune environment and alleviate skin lesions.
- Other names
- CIK cellsautologous CIK cellsadoptive immunotherapy-Chinese PLA General Hospital-plaque psoriasis
Beyond the preview
Go deeper on autologous cytokine-induced killer cells (Chinese PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous cytokine-induced killer cells (Chinese PLA General Hospital).